Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline partners with Gilead to commercialise Viread

GlaxoSmithKline partners with Gilead to commercialise Viread

25th November 2009

GlaxoSmithKline has revealed that it plans to work with Gilead to commercialise Viread (tenofovir disoproxil fumarate), a drug for the treatment of chronic hepatitis B (HBV) in adults.

The joint commercialisation efforts of the firms will increase access to the drug to patients who have not yet used it.

As part of the new contract, Gilead will retain the rights to Viread in markets such as Hong Kong, Singapore and Taiwan, while GlaxoSmithKline will be responsible for its registration and commercialisation in China.

“The agreement with Gilead to develop and launch Viread in China builds on [our] strong heritage in hepatitis B and provides an important addition to GlaxoSmithKline’s current portfolio in one of our key markets,” commented Abbas Hussain, president of emerging markets at GlaxoSmithKline.

GlaxoSmithKline entered into another partnership of this month – that with fellow pharmaceutical firm with Nabi – which will see the two companies manufacture a vaccine to prevent nicotine addiction.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.